Merck to license investigational insulin sensitizer NGM313 from NGM Bio to treat NASH and type 2 diabetes

Merck to license investigational insulin sensitizer, NGM313 from NGM Bio to treat NASH and type 2 diabetes

Merck known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody

More From BioPortfolio on "Merck to license investigational insulin sensitizer, NGM313 from NGM Bio to treat NASH and type 2 diabetes"